Abstract: A solution is the microorganism testing apparatus equipped with a pre-processing unit in which, if a content of microorganism testing on a specific specimen is selected or input, testing conditions of the specimen read from a storage device in which testing information specifying the testing conditions of the specimen is stored are printed on a sheet-form medium to be used for testing of the specimen, and a post-processing unit in which, if an image of the medium is read, the testing conditions printed on the medium and a type of the medium preliminarily labelled on the medium are acquired from the image to output judgment results as to whether or not the testing conditions acquired from the image, and the type of the medium are compatible.

Abstract: A solution is the microorganism testing apparatus equipped with a pre-processing unit in which, if a content of microorganism testing on a specific specimen is selected or input, testing conditions of the specimen read from a storage device in which testing information specifying the testing conditions of the specimen is stored are printed on a sheet-form medium to be used for testing of the specimen, and a post-processing unit in which, if an image of the medium is read, the testing conditions printed on the medium and a type of the medium preliminarily labelled on the medium are acquired from the image to output judgment results as to whether or not the testing conditions acquired from the image, and the type of the medium are compatible.

Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.

Abstract: Provided by the present invention are an anti-coagulant comprising a polysaccharide having a structural unit in which an abundance ratio of glucose, glucuronic acid and rhamnose is 2:1:1 mole, preferably a polysaccharide having a structural unit represented by Formula (1) and more preferably a compound obtained by partially sulfating a hydroxyl group of gellan and an anti-thrombus agent or a blood contact face-treating agent for medical equipment comprising this anti-coagulant.

Abstract: A drug is provided comprising of a degradable gel with a saturated moisture content not exceeding 98 wt. % and a functional material, and which permits control of the rate of release of the functional material and performs controlled-release of the functional material over a prolonged period of time, and wherein the gel itself decomposes and dissipates upon completion of release of the functional material.

Abstract: To provide degradable gel hardly degradable and having enough strength, and a method for producing the same.

Abstract: This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.

Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.

Abstract: This invention relates to a chemically modified hyaluronic acid and salts thereof, which are obtained by O-acylating, alkoxylating or crosslinking a complex consisting of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent, and a process for the production thereof. The nonaqueous solvent used in the invention is preferably one or more solvents selected from the group consisting of chloroform, toluene, methylene chloride and heptane.

Abstract: To determine the oxygen saturation and other parameters of blood flowing in a fetus positioned in the uterus by detecting the pulsation of the blood in the birthing process from the rupture of the water membrane to the delivery of the baby. An opening is formed near the distal end of a curved support member and both light-emitting portion and light-receiving portion are positioned in the opening as they are spaced apart by a specified gap in which the head of a fetus is rested for detecting the pulsation of blood using measurements of transmitted light.

Abstract: An electromagnetic flow meter comprising a circuit for generating signals proportional to the intensity of an A.C. magnetic field impressed on a fluid running through a pipe; a first switch rendered conducting for a prescribed period simultaneously with an A.C. voltage obtained in proportional to the period of the A.C. magnetic field; a second switch actuated after the conduction of the first switch; a circuit for integrating outputs corresponding to the flow rate of a fluid obtained through the first switch and further integrating said outputs with an opposite polarity; a circuit for rendering the second switch nonconducting when an output from said integration circuit reaches a referential level; and a circuit for generating an output corresponding to the period in which said outputs are integrated, for each operating cycle of said integration circuit.